CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04745832
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:09.762768+00:00
Published At: 2023-12-13T00:00:00+00:00
Record Updated At: 2024-11-04
Results Posted At: 2023-12-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Follicular Lymphoma (FL)", "Non Hodgkin Lymphoma", "Marginal Zone Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-11-04"
protocolSection.identificationModule.nctId: "NCT04745832"
protocolSection.identificationModule.officialTitle: "A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin\u0027s Lymphoma (iNHL) - The COASTAL Study"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-12-13"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.